6
NEWS
Latest IDDT newsletters
The latest IDDT Newsletters are now available on our website.
The September 2024 issue of the Newsletter includes articles on:
• Metformin and Type 1 diabetes
• Diabetes distress
• Sick-day guidance for people with Type 1 or Type 2 diabetes
The September 2024 issue of Type 2 & You includes articles on:
• NHS expands 'soup and shake' diets to more people with Type 2 diabetes
• New home devices for sleep apnoea
• Diabetes and Flu
To view the September Newsletter click here
To view the September issue of Type 2 and You click here
Vertex new data on 'cure'
for T1D
Vertex has presented new data on its clinical trial VX-880, hailed as a
potentially revolutionary treatment for people with Type 1 diabetes.
VX-880 is a type of experimental stem cell therapy which aims
to restore natural insulin production in people with Type 1 diabetes.
It works by transplanting healthy insulin-producing cells into the
body. If successful, the new cells would replace non-functioning
ones and ultimately restore insulin production. Similar to people
who receive organ transplants, those treated with VX-880 must
take immunosuppressants to prevent the immune system from
rejecting new beta cells. Because of the risk of infection associated
with immunosuppressants, only those with severe hypoglycaemia
unawareness have been eligible for the trial, as these have the most to
gain from this type of therapy.
The results of the study so far have been promising. All 12
participants who received a full dose of VX-880 saw a reduction in
A1C of less than 7% and no longer experienced severe hypoglycaemia.
Eleven had either a reduced need for or complete elimination of
exogenous insulin (injectable insulin not naturally produced by
the body). In addition, all participants experienced significant
improvements in A1C, time in range, as well as a reduced need for
insulin injections.
Of the four participants who passed the one-year mark following
treatment, all achieved insulin independence and maintained an A1C
of less than 7%. This indicates that VX-880 could be a much-awaited
functional "cure" for Type 1 diabetes. However, while the results
so far are exciting, research is still in the early stages. The current
trial is anticipated to wrap up in 2030, and additional studies with
larger sample sizes would need to follow. After all of the studies are
completed, Vertex would need to submit an application to the FDA
before it can be approved for use.
To find out more, CLICK HERE
Beta Bionics
and FSL3+
Beta Bionics has announced that it has
partnered with Abbott (NYSE:ABT) to
integrate the company's CGM with its
automated insulin delivery system.
The companies plan to combine
Abbott's FreeStyle Libre 3 Plus
continuous glucose monitor (CGM) with
the Beta Bionics iLet bionic pancreas.
According to Beta Bionics, this will make
iLet the first available AID system to
integrate with Libre 3 Plus in the U.S
when it is launched in the fourth quarter
of 2024.
Beta Bionics designed its iLet
autonomous insulin delivery system
to streamline diabetes management.
The system, which reduces the burden
on patients and physicians, received
FDA clearance in May 2023. It uses an
adaptive, closed-loop algorithm that
initializes with the user's body weight
and requires no additional insulin dosing
parameters not any need to manually
adjust insulin pump therapy settings
and variables. iLet users only input their
weight, then the system does the rest.
To find out more, CLICK HERE